Nemes Rush Group’s Vertex Pharmaceuticals VRTX Stock Holding History

Nemes Rush Group’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.5M	Sell	5,605 -132	-2%	-$61.6K	0.24%	68
2025 Q4	$2.6M	Sell	5,737 -13	-0.2%	-$5.6K	0.24%	66
2025 Q3	$2.25M	Buy	5,750 +27	+0.5%	+$11.3K	0.22%	71
2025 Q2	$2.55M	Buy	5,723 +977	+21%	+$450K	0.28%	65
2025 Q1	$2.3M	Sell	4,746 -112	-2%	-$52.2K	0.29%	59
2024 Q4	$1.96M	Buy	4,858 +142	+3%	+$65.8K	0.24%	65
2024 Q3	$1.97M	Sell	4,716 -9	-0.2%	-$4.32K	0.29%	65
2024 Q2	$2.21M	Buy	4,725 +9	+0.2%	+$3.91K	0.3%	58
2024 Q1	$1.97M	Sell	4,716 -18	-0.4%	-$7.61K	0.28%	65
2023 Q4	$1.93M	Sell	4,734 -32	-0.7%	-$11.8K	0.31%	62
2023 Q3	$1.66M	Sell	4,766 -18	-0.4%	-$6.29K	0.3%	67
2023 Q2	$1.68M	Buy	+4,784	New	+$1.61M	0.3%	69

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Nemes Rush Group's VRTX Position: Q1 2026 in Review

Nemes Rush Group reduced its Vertex Pharmaceuticals (VRTX) stake by 2.3% in Q1 2026, selling an estimated $61.6K and leaving 5,605 shares worth $2.5M. The position accounts for 0.24% of the portfolio, ranked #68.

Nemes Rush Group first reported a position in VRTX in Q2 2023 and has held it in 12 quarters since. The position peaked at $2.6M in Q4 2025. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

Nemes Rush Group held 5,605 shares of Vertex Pharmaceuticals worth $2.5M as of Q1 2026.
Nemes Rush Group sold 132 Vertex Pharmaceuticals shares in Q1 2026, an estimated $61.6K.
Vertex Pharmaceuticals made up 0.24% of Nemes Rush Group's portfolio in Q1 2026, its #68 holding.
Nemes Rush Group first reported a position in Vertex Pharmaceuticals in Q2 2023 and has held it in 12 quarters since.
Nemes Rush Group's Vertex Pharmaceuticals position peaked at $2.6M in Q4 2025.
1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Nemes Rush Group's 13F filing for Q1 2026, filed 21 Apr 2026.